Morgan Stanley analyst Judah Frommer maintained a Buy rating on Kymera Therapeutics today and set a price target of $123.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Judah Frommer has given his Buy rating due to a combination of factors tied to Kymera’s progress and market positioning in immunology. He sees a sizable commercial runway in type 2 inflammatory diseases, noting that millions of patients remain undertreated and that experience from markets such as psoriasis suggests room for several new entrants, especially those offering differentiated profiles like oral administration.
Frommer also highlights KT-621’s strong early efficacy and safety data and its convenient oral route as key advantages as it advances through Phase 2b trials. In parallel, he views KT-579 as an emerging value driver, with upcoming Phase 1 healthy volunteer data expected to demonstrate potent IRF5 degradation and pathway modulation that could translate into efficacy in lupus, all supported by a cash runway projected to extend into 2029.
According to TipRanks, Frommer is a 2-star analyst with an average return of 0.7% and a 49.81% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, Incyte, and PTC Therapeutics.